about
Preference for pharmaceutical formulation and treatment process attributesA Review of Patient Preferences for Osteoporosis Drug TreatmentEffect of transdermal teriparatide administration on bone mineral density in postmenopausal women.Low acceptance of treatment in the elderly for the secondary prevention of osteoporotic fracture in the acute rehabilitation settingIf you don't take it - it can't work: the consequences of not being treated or nonadherence to osteoporosis therapy.What are the essential elements to enable patient participation in medical decision making?Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis.Benefit from preoperative radiotherapy in rectal cancer treatment: disease-free patients' and oncologists' preferencesAdaptive choice-based conjoint analysis: a new patient-centered approach to the assessment of health service preferences.Patients' preferences for osteoporosis drug treatment: a discrete choice experiment.Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs.Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives?Methodologic evaluation of adaptive conjoint analysis to assess patient preferences: an application in oncology.Treatment of postmenopausal osteoporosis, patient perspectives - focus on once yearly zoledronic acidPatients' preferences for osteoporosis drug treatment: a discrete-choice experiment.Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.Patient preferences for osteoporosis in Spain: a discrete choice experiment.How important is mode of administration in treatments for rheumatic diseases and related conditions?Patient-reported outcomes in core domain sets for rheumatic diseases.Compliance, Persistence, and Preferences Regarding Osteoporosis Treatment During Active Therapy or Drug Holiday.A Comparison of Methods for Capturing Patient Preferences for Delivery of Mental Health Services to Low-Income Hispanics Engaged in Primary Care.Persistence to medical treatment of osteoporosis in women at three different clinical settings--a historical cohort study.Anti-osteoporotic therapy in Denmark--predictors and demographics of poor refill compliance and poor persistence.Patient weighting of osteoporosis medication attributes across racial and ethnic groups: a study of osteoporosis medication preferences using conjoint analysis.Randomized trial of presenting absolute v. relative risk reduction in the elicitation of patient values for heart disease prevention with conjoint analysis.Preference elicitation tool for abnormal uterine bleeding treatment: a randomized controlled trial.The effects of neuromuscular facilitation techniques on osteoporosis of hemiplegia limbs and serum leptin level in patients or rats with cerebral infarction.Patient Preferences of a Low-Income Hispanic Population for Mental Health Services in Primary Care.
P2860
Q26741298-38CA042D-AA40-4C7B-B935-A6603FA2E2ADQ26796811-0673EBF6-888E-4B59-B105-F95F063A0D61Q33586747-7ABD536E-CA89-414F-A4D0-1B19460C621EQ34055595-A7DBEB0A-8B96-40DD-9CE1-1E7BA63DCE1AQ35050249-906F0A0C-6491-47DF-A2FF-FCF7CE8DD785Q35758235-F61C0BB3-0B01-4663-B7B6-C023A90D1878Q36610799-08973C42-E945-46B2-BBC3-5BE729839203Q36611201-5B9187CB-368D-46DB-A45F-50F17FE01E41Q36632070-3B6B20CA-1EAA-43B2-AC72-973826ABE36CQ36738207-9A767D2D-4076-42B9-A858-DFB61CC207B9Q36979427-AF20AC5D-96B6-4B66-9C31-9A771A1FAA8FQ37122841-F90446E2-708C-4F13-9F3A-B79C3EB33340Q37332615-6D6445CC-45BB-458E-A16A-40A26315E863Q37423723-A9A93E79-97D2-439C-8A46-A4010A06A400Q37691108-9F5D032E-F2EA-4C39-A21B-9DCE918FF01BQ37768696-1645BD44-8369-49A2-B0D5-903D961283C6Q37788571-2B5E09F5-7864-482F-92E0-956784C04EA6Q38436502-78905778-2C8F-46D3-AC25-A1E834D5DB77Q38577796-90676169-6F8F-4BA1-8A2E-97682E8D0385Q38892167-8D739D76-9AF6-4CB9-9123-BDB002AB27AAQ40186513-C361FEBF-7268-4642-9086-28B1A45DCD32Q43059573-E259F304-157E-4228-AFB5-128CB4D706ABQ43678564-CE9EB9DD-AEFE-416B-87A9-6E0C4DC97A25Q44954320-228ED82A-BB1D-4C42-A594-2D9D73C98561Q46326295-39723D4E-72D7-4031-BCB6-AF0452DB7732Q47839021-6D68D8A2-5B2E-4176-9CCD-C47CC783B413Q48846448-D5A668D8-F1D6-4552-8B34-19F427C30315Q50562687-18BF17F8-768E-427B-9F88-A3FA7C66EB5C
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Patient treatment preferences for osteoporosis
@ast
Patient treatment preferences for osteoporosis
@en
type
label
Patient treatment preferences for osteoporosis
@ast
Patient treatment preferences for osteoporosis
@en
prefLabel
Patient treatment preferences for osteoporosis
@ast
Patient treatment preferences for osteoporosis
@en
P2093
P2860
P356
P1476
Patient treatment preferences for osteoporosis
@en
P2093
Barbara Gulanski
Dick Wittink
Liana Fraenkel
P2860
P304
P356
10.1002/ART.22229
P577
2006-10-01T00:00:00Z